IP Library › Granted Patent US 12,605,485
Granted Patent B2
US 12,605,485 · App. 17/973,640 · Granted Apr 21, 2026

Nanoparticles to promote wound healing and antimicrobial infection control

Inventor: Christina H. Drake (Winter Park, FL)
Assignee: Kismet Technologies Inc.
A61L26/0066A61K9/14A61K33/00A61K33/24A61K33/242A61K33/243A61K33/26A61K33/30A61K33/34A61K33/38A61K38/19A61K47/10A61K47/34A61K47/36A61K47/42A61L26/0095A61P27/02A61K48/00A61L2300/104A61L2300/402A61L2300/404A61L2300/41A61L2400/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,605,485
App. No.
17/973,640
Granted
Apr 21, 2026
Kind
B2
Abstract

A wound healing composition is provided that includes a tissue adhesive or epithelial tissue healing agent and metal-modified cerium oxide nanoparticles (mCNPs). The nCNPs have a predominant 3+ surface charge and are in a range of about 3-35 nanometers (nm) in size and mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive or epithelial tissue healing agent and the mCNPs. The metal (m) is a stable metallic metal with antimicrobial properties and non-ionizing. The mCNPs includes AgCNP2. A method is provided that uses the healing composition to treat a wound or epithelial tissue. The composition can be used to treat the skin or eye and/or subcutaneous tissue.

Claims (38)

1 . A wound healing composition comprising:

a tissue adhesive; and

silver-modified cerium oxide nanoparticles (AgCNPs) consisting of a predominant Ce3+ surface charge mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive and the AgCNPs wherein the AgCNPs include stable metallic silver (Ag) that is non-ionizing, a Janus-type two-phase construct and an antimicrobial promoting metal wherein about is at least one of 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the range.

2 . The wound healing composition according to claim 1 , wherein the tissue adhesive is a therapeutically effective amount of a surgical adhesive.

3 . The wound healing composition according to claim 1 , wherein the tissue adhesive comprises one of cyanoacralate, 2-octyl cyanoacrylate or fibrin glue.

4 . The wound healing composition according to claim 1 , wherein the tissue adhesive includes a hydrogel consisting of at least one of polyethylene glycol (PEG), fibrin, a dextran suitable for chemical crosslinking, a dextran suitable for photo-crosslinking, albumin or polyacrylamide.

5 . The wound healing composition according to claim 1 , the adhesive comprises non-degradable materials selected from a group consisting of: expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polyethyleneterephthalate (PET), polyurethane, polyethylene, polycarbonate, polystyrene, silicone, or degradable materials that include one of poly (lactic-co-glycolic acid; PLGA), polylactic acid (PLA), or polyglycolic acid (PGA).

6 . A wound healing composition comprising:

an epithelial tissue healing agent; and

silver-modified cerium oxide nanoparticles (AgCNPs) consisting of a predominant Ce3+ surface charge mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the epithelial tissue healing agent and the AgCNPs wherein the AgCNPs include a stable metallic silver (Ag) that is non-ionizing and a Janus-type two-phase construct wherein about is at least one of 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the range.

7 . The wound healing composition according to claim 6 , wherein the epithelial tissue healing agent is selected from a group consisting of a preadipocyte modulator and an adipocyte modulator and contains in a pharmaceutically acceptable composition for subcutaneous administration.

8 . The wound healing composition according to claim 6 , wherein the epithelial tissue healing agent of the mixture contains a polynucleotide in a pharmaceutically acceptable carrier for skin tissue administration.

9 . The wound healing composition according to claim 6 , wherein the epithelial tissue healing agent of the mixture is selected from a group consisting of preadipocyte modulator and an adipocyte modulator and contains in a pharmaceutically acceptable composition for ocular tissue administration.

10 . The wound healing composition according to claim 6 , wherein the epithelial tissue healing agent of the mixture contains a pharmaceutically acceptable carrier for ocular tissue administration.

11 . The wound healing composition according to claim 6 , wherein the epithelial tissue healing agent of the mixture comprises a viral vector comprising polynucleotide coding for an adipokine to transform skin cells to express and secrete adipokine.

12 . A method comprising:

treating skin tissue of a wound with a wound healing composition of claim 1 .

13 . The method according to claim 12 , wherein the wound is a surgical incision formed in the skin tissue.

14 . A method comprising:

treating epithelial tissue with a wound healing composition of claim 8 .

15 . The method according to claim 14 , wherein the epithelial tissue is ocular tissue.

16 . The method according to claim 14 , wherein the epithelial tissue is skin cells and the treating includes:

administering to the skin cells colonizing damaged skin or a skin wound area a therapeutically effective amount of the wound healing composition,

wherein the epithelial tissue healing agent of the mixture includes a viral vector comprising a polynucleotide coding for an adipokine.

17 . The method according to claim 14 , wherein the epithelial tissue is skin cells and the treating includes:

administering to the skin cells colonizing damaged skin or a skin wound area of ocular tissue a therapeutically effective amount of the wound healing composition,

wherein the epithelial tissue healing agent of the mixture is selected from a group consisting of preadipocyte modulator and an adipocyte modulator and contains in a pharmaceutically acceptable composition for the ocular tissue.

18 . The method according to claim 12 , wherein the epithelial tissue is skin cells of a surgical incision and the treating includes:

administering to the skin cells a therapeutically effective amount of the wound healing composition,

wherein the tissue adhesive of the mixture includes a therapeutically effective amount of a surgical adhesive.

19 . The method according to claim 12 , wherein the epithelial tissue is skin cells and the treating includes:

administering to the skin cells colonizing damaged skin or a skin wound area a therapeutically effective amount of the wound healing composition,

wherein the tissue adhesive of the mixture includes a hydrogel consisting of at least one of polyethylene glycol (PEG), fibrin, a dextran suitable for chemical crosslinking, a dextran suitable for photo-crosslinking, albumin or polyacrylamide.

20 . A wound healing composition consisting of:

a tissue adhesive; and

metal-modified cerium oxide nanoparticles (mCNPs) consisting of a predominant Ce3+ surface charge mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive and the mCNPs wherein the m is an antimicrobial promoting metal consisting of one of silver, gold, or platinum wherein about is at least one of 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the range.

21 . The wound healing composition according to claim 1 , wherein the predominant Ce3 surface charge is greater than 53.7 percent.

22 . The wound healing composition according to claim 6 , wherein the predominant Ce3+ surface charge is greater than 53.7 percent.

Assignments (2)
CONVERSION Recorded Feb 7, 2024
From: KISMET TECHNOLOGIES LLC
To: KISMET TECHNOLOGIES INC.
Reel/Frame 066508/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2023
From: DRAKE, CHRISTINA H.
To: KISMET TECHNOLOGIES LLC
Reel/Frame 064791/0163 →
Continuity (2)
Provisional Application 63272930 · Oct 28, 2021
Related Publication 20230137084A1 · May 4, 2023
References Cited (62)
US 4826893A · Yamazaki et al. · 1989 [cited by applicant]
US 4866042A · Neuwelt · 1989 [cited by applicant]
US 5223425A · Flier et al. · 1993 [cited by applicant]
US 5290552A · Sierra et al. · 1994 [cited by applicant]
US 5464764A · Capecchi et al. · 1995 [cited by applicant]
US 5487992A · Capecchi et al. · 1996 [cited by applicant]
US 7638484B2 · Braiman-Wilksman et al. · 2009 [cited by applicant]
US 8400408B2 · Hotelling et al. · 2013 [cited by applicant]
US 8507431B2 · Braiman-Wilksman et al. · 2013 [cited by applicant]
US 10155361B2 · Bookbinder et al. · 2018 [cited by applicant]
US 10289225B2 · Jin et al. · 2019 [cited by applicant]
US 10642426B2 · Hwang et al. · 2020 [cited by applicant]
US 10925773B2 · Riesinger · 2021 [cited by applicant]
US 20060155041A1 · Suzuki · 2006 [cited by examiner]
US 20090130157A1 · Ylitalo et al. · 2009 [cited by applicant]
US 20110002971A1 · Hassler et al. · 2011 [cited by applicant]
US 20120020917A1 · Braiman-Wiksman · 2012 [cited by examiner]
US 20120107556A1 · Zhang et al. · 2012 [cited by applicant]
US 20130115441A1 · Bookbinder et al. · 2013 [cited by applicant]
US 20130195927A1 · Sudipta · 2013 [cited by examiner]
US 20130211028A1 · Shinike et al. · 2013 [cited by applicant]
US 20150059237A1 · Difrancesco · 2015 [cited by examiner]
US 20160158403A1 · Watson · 2016 [cited by applicant]
US 20160194503A1 · Karl · 2016 [cited by applicant]
US 20170202965A1 · Baker · 2017 [cited by applicant]
US 20170232139A1 · Brownlee et al. · 2017 [cited by applicant]
US 20170252320A1 · Martins-Green et al. · 2017 [cited by applicant]
US 20180028431A1 · Chiattello et al. · 2018 [cited by applicant]
US 20180110658A1 · Lin · 2018 [cited by applicant]
US 20180339913A1 · Seal et al. · 2018 [cited by applicant]
US 20190111424A1 · Chou et al. · 2019 [cited by applicant]
US 20190262393A1 · Pesavento · 2019 [cited by applicant]
US 20190275195A1 · Leibler et al. · 2019 [cited by applicant]
US 20210030656A1 · Liechty et al. · 2021 [cited by applicant]
CA 2644315 · 2007 [cited by applicant]
CN 101138342 · 2011 [cited by applicant]
CN 102559138 · 2012 [cited by applicant]
WO 2005013885 · 2005 [cited by applicant]
WO 2017011886 · 2017 [cited by applicant]
WO 2021222779 · 2021 [cited by applicant]
Sadidi et al (Molecules, Oct. 6, 2020 (online), vol. 25, pp. 1-25) (Year: 2020). [cited by examiner]
Neal et al (ACS Nano, Aug. 2021, vol. 15, pp. 14544-14556) (Year: 2021). [cited by examiner]
Hanafy et al (Molecules, Jan. 2020, vol. 25, pp. 1-16) (Year: 2020). [cited by examiner]
Maleki et al (Inorganic Chemistry Communications, Jun. 2021, vol. 131, pp. 1-9). (Year: 2021). [cited by examiner]
Mitchell et al (Nature Communications, Nov. 2017, vol. 8, pp. 1-7) (Year: 2017). [cited by examiner]
International Search Report, Feb. 14, 2023. [cited by applicant]
Neal, Craig J. et al., “schemMetal-Mediated Nanoscale Cerium Oxide Inactivates Human Coronavirus and Rhinovirus , by Surface Disruption,” ACS Nano, 2021, 15(9), 14544-14556. doi: 10.1021/acsnano.1c04142. [cited by applicant]
Szczesio-Wlodarczyk, A. et al., “An Evaluation of the Properties of Urethane Dimethacrylate-Based Dental Resins,” Materials, 2021, 14(11):2727. https://doi.org/10.3390/ma14112727. [cited by applicant]
Xu, Z. et al., “Advances and Impact of Antioxidant Hydrogel in Chronic Wound Healing,” Advanced Healthcare Materials, 2020, 9, 1901502. 10.1002/adhm.201901502. [cited by applicant]
Woodhouse, Ian et al., “Flexible Microneedle Array Patch for Chronic Wound Oxygenation and Biofilm Eradication,” ACS Applied Bio Materials, 2021, 4 (7), 5405-5415. doi: 10.1021/acsabm.1c00087. [cited by applicant]
Cheng et al., “Developing a New Generation of Antimicrobial and Bioactive Dental Resins,” Journal of Dental Research, 2017, vol. 96(8): 855-863, doi: 10.177/0022034517709739. [cited by applicant]
Shcherbakov et al., “Ce02 Nanoparticles-Containing Polymers for Biomedical Applications: A Review,” Mar. 17, 2021, Polymers 2021, 3, 924, www.doi.org/10.3390/polym3060924. [cited by applicant]
OECD Guideline for the Testing of Chemicals No. 439, “In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method,” Jul. 23, 2010, OECD Publishing, Paris, https://doi.org/10.1787/9789264090958-en. [cited by applicant]
Wan, David, (2015). U.N. Ghs: United Nations Globally Harmonized System of Classification and Labeling of Chemicals. CIRS. https://www.cirs-group.com/en/chemicals/un-ghs-globally-harmonized-system-of-classification-and-… [cited by applicant]
OECD (2021), Test No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264242845-en. [cited by applicant]
European Commission Joint Research Centre, “Statement on the Scientific Validity of In-Vitro Tests for Skin Irritation Testing,” Institute for Health and Consumer Protection In-vitro Toxicology Unit, European Centre for… [cited by applicant]
OECD Guidelines for the Testing of Chemicals, Test Guideline No. 492, “Reconstructed Human Cornea-like Epithelium (RhCE) Test Method for Identifying Chemicals Not Requiring Classification and Labelling for Eye Irritatio… [cited by applicant]
Gwak, J.H. et al., “Identifying the trends in wound healing patents for successful investment strategies,” PLoS One, 2017, 12(3): e0174203. https://doi.org/10.1371/journal.pone.0174203. [cited by applicant]
GHS: Globally Harmonized System of Classification and Labeling of Chemicals (GHS), 8th revised edition, 2019. United Nations—New York and Geneva. [cited by applicant]
Meng, Z. et al., “Therapeutic Considerations and Conjugated Polymer-Based Photosensitizers for Photodynamic Therapy,” Macromolecular Rapid Communications, 2017, 1700614. doi: 10.1002/marc.201700614. [cited by applicant]
Bhattacharya, Dipsikha et al., “Accelerated and scarless wound repair by a multicomponent hydrogel through simultaneous activation of multiple pathways,” Drug Delivery and Translational Research. Dec. 2019;9(6):1143-115… [cited by applicant]
Kalaycolu, Z. et al., “Antibacterial Nano Cerium Oxide/Chitosan/Cellulose Acetate Composite Films as Potential Wound Dressing,” European Polymer Journal (2020), doi: https://doi.org/10.1016/j.eurpolymj.2020.109777. [cited by applicant]